Genmab A/S’s (GMAB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $50.00 price objective on the stock.

GMAB has been the topic of a number of other research reports. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Price Performance

Shares of GMAB stock opened at $22.15 on Wednesday. Genmab A/S has a one year low of $19.85 and a one year high of $31.97. The stock has a market cap of $14.66 billion, a P/E ratio of 21.51, a P/E/G ratio of 0.63 and a beta of 0.97. The company has a fifty day moving average price of $21.31 and a two-hundred day moving average price of $24.22.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the firm earned $0.47 earnings per share. As a group, equities research analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors have recently added to or reduced their stakes in the business. Two Sigma Advisers LP lifted its holdings in shares of Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Genmab A/S in the 2nd quarter worth $1,354,000. Finally, Natixis Advisors LLC lifted its position in shares of Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after buying an additional 47,437 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.